Listed

KORU Medical Systems, Inc.: Form 10-Q for the period ended Jun 30, 2021

Filed with the SEC on Aug 11, 2021 and accepted by EDGAR at Aug 11, 2021, 17:07 ET.

Share

Management's discussion and analysis

As filed, 3,040 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company issued an aggregate 14,615 shares of common stock to its non-employee directors during the three months ended June 30, 2021 in accordance with its non-employee director compensation program.

All of the securities issued by the Company as described in this Item were issued in reliance on the exemption from registration under Section 4(2) under the Securities Act of 1933, as amended.

Issuer Purchases of Equity Securities

On November 16, 2020, the Company announced that its Board of Directors had authorized a stock repurchase program under which the Company may choose to purchase up to $10.0 million of its outstanding common stock through December 31, 2021. As of December 31, 2020, the Company had purchased 683,271 shares for an aggregate $3,499,358 pursuant to this program. No purchases have been made since that time, as we continue to evaluate our cash needs in connection with strategic planning under the leadership of our new Chief Executive Officer.

- 21 -

PART II – ITEM 6. EXHIBITS.

10.1 Summary of Non-Employee Director Compensation (effective May 18, 2021)
10.2 Repro Med Systems, Inc. 2021 Omnibus Equity Incentive Plan
10.3 Form of non-qualified/incentive stock option award agreement pursuant to the 2021 Omnibus Equity Inventive Plan
10.4 Form of Indemnification Agreement between Repro Med Systems, Inc. and each of its directors and executive officers
31.1 Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002
31.2 Certification of Principal Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002
32.1 Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002
32.2 Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002
101.INS Inline XBRL Instance Document - the XBRL Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

- 22 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

REPRO MED SYSTEMS, INC.
August 11, 2021 /s/ Linda Tharby
Linda Tharby, President and Chief Executive Officer (Principal Executive Officer)
August 11, 2021 /s/ Karen Fisher
Karen Fisher, Chief Financial Officer and Treasurer (Principal Financial Officer)

- 23 -

Controls and procedures

As filed, 1,345 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company’s management, including the Company’s Principal Executive Officer and Principal Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures as such is defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based upon their evaluations, the Principal Executive Officer and Principal Financial Officer concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were effective for the purpose of ensuring that the information required to be disclosed in the reports that the Company files or submits under the Exchange Act with the Securities and Exchange Commission (the “SEC”) (1) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (2) is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

There have been no changes in the Company’s internal control over financial reporting during the three months ended June 30, 2021, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

Risk factors

As filed, 490 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our operations and financial results are subject to various risks and uncertainties, including those described in “PART 1, ITEM 1A. RISK FACTORS” in our Annual Report on Form 10-K for the year ended December 31, 2020, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common stock. There have been no material changes to our risk factors since our Annual Report on Form 10-K for the year ended December 31, 2020.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-04-01 to 2021-06-30$5.5mus-gaap:Revenues
Revenue6 months2021-01-01 to 2021-06-30$11.0mus-gaap:Revenues
Cost of revenue3 months2021-04-01 to 2021-06-30$2.3mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue6 months2021-01-01 to 2021-06-30$4.5mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2021-04-01 to 2021-06-30$3.2mus-gaap:GrossProfit
Gross profit6 months2021-01-01 to 2021-06-30$6.4mus-gaap:GrossProfit
Research and development3 months2021-04-01 to 2021-06-30$386.9kus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2021-01-01 to 2021-06-30$723.7kus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2021-04-01 to 2021-06-30$4.1mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2021-01-01 to 2021-06-30$9.1mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2021-04-01 to 2021-06-30−$1.4mus-gaap:OperatingIncomeLoss
Operating income6 months2021-01-01 to 2021-06-30−$3.6mus-gaap:OperatingIncomeLoss
Income tax3 months2021-04-01 to 2021-06-30−$245.3kus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2021-01-01 to 2021-06-30−$1.2mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-04-01 to 2021-06-30−$1.1mus-gaap:NetIncomeLoss
Net income6 months2021-01-01 to 2021-06-30−$2.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2021-04-01 to 2021-06-30−$0.03us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2021-01-01 to 2021-06-30−$0.05us-gaap:EarningsPerShareDiluted
Basic EPS3 months2021-04-01 to 2021-06-30−$0.03us-gaap:EarningsPerShareBasic
Basic EPS6 months2021-01-01 to 2021-06-30−$0.05us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2021-04-01 to 2021-06-3044,489,853 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2021-01-01 to 2021-06-3044,226,936 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2021-01-01 to 2021-06-30−$2.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2021-01-01 to 2021-06-30$152.2kus-gaap:PaymentsToAcquireProductiveAssets
Cash and equivalentsAt period end2021-06-30$26.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-06-30$37.1mus-gaap:AssetsCurrent
Total assetsAt period end2021-06-30$40.6mus-gaap:Assets
Current liabilitiesAt period end2021-06-30$3.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-06-30$3.3mus-gaap:Liabilities
Shareholders' equityAt period end2021-06-30$37.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001161697-21-000374. Last ingested by Listed: Nov 11, 2026, 02:24 ET. Listed shows no prices and gives no investment advice.